Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4143632 | 0.90 | CASR (0.61) | CASRNR1I2 | |
| SCHEMBL3379049 | 0.87 | CASR (0.87) | CASRNR1I2 | |
| SCHEMBL4142998 | 0.86 | CASR (0.75) | CASRNR1I2 | |
| SCHEMBL3382480 | 0.86 | CASR (0.70) | CASRNR1I2 | |
| SCHEMBL3380160 | 0.85 | CASR (0.74) | CASRNR1I2 | |
| SCHEMBL3380781 | 0.82 | CASR (0.70) | CASRNR1I2 | |
| SCHEMBL3382630 | 0.82 | CASR (0.69) | CASRNR1I2 | |
| SCHEMBL3383210 | 0.82 | CASR (0.69) | CASRNR1I2 | |
| SCHEMBL3382361 | 0.82 | CASR (0.69) | CASRNR1I2 | |
| SCHEMBL13851574 | 0.81 | CASR (0.51) | CASRNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615897-B1 | PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMA INC (US) | 2010-11-24 | — | — | EP | claimed |
| US-7491728-B2 | Pyrimidinone compounds as calcilytics | SMITHKLINE BEECHAM CORP. (US) | 2009-02-17 | — | — | US | claimed |
| EP-1615897-A4 | PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMA INC (US) | 2008-07-23 | — | — | EP | claimed |
| US-20070197555-A1 | Pyrimidinone Compounds As Calcilytics | GLAXOSMITHKLINE LLC | 2007-08-23 | — | — | US | claimed |
| CN-1835928-A | Pyrimidone compounds as calcium-sensitive receptor antagonists | NPS PHARMA INC (US) | 2006-09-20 | — | — | CN | claimed |
| EP-1615897-A2 | PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2006-01-18 | — | — | EP | claimed |
| WO-2004092120-A2 | PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | claimed |
| EP-1615897-B1 | PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMA INC (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7491728-B2 | Pyrimidinone compounds as calcilytics | SMITHKLINE BEECHAM CORP. (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1615897-A4 | PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMA INC (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070197555-A1 | Pyrimidinone Compounds As Calcilytics | GLAXOSMITHKLINE LLC | 2007-08-23 | — | — | US | disclosed |
| CN-1835928-A | Pyrimidone compounds as calcium-sensitive receptor antagonists | NPS PHARMA INC (US) | 2006-09-20 | — | — | CN | disclosed |
| EP-1615897-A2 | PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004092120-A2 | PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197555-A1 | Pyrimidinone Compounds As Calcilytics | TYMP, DPYD, UMPS | CASR 286/4885NR1I2 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.